肿瘤多药耐药蛋白MRP1、LRP和GST-π在胆囊和胆管癌组织中的表达

目的 探讨多药耐药(MDR)基因产物多药耐药相关蛋白(MRP1)、肺耐药蛋白(LRP)和谷胱甘肽S-转移酶-π(GST-π)在胆囊癌和胆管癌中的表达及其与耐药的关系.方法 采用免疫组化的方法(IHC)检测实验组18例胆囊癌、36例胆管癌及对照组13例胆囊胆管炎症组织中MRP1、LRP及GST-π的表达情况,采用x2检验和Spearman检验. 结果 MRP.、LRP和GST-π在胆囊癌组织中的表达阳性率分别72%(13/18)、78%(14/18)和61%(11/18),在胆管癌组织中的表达阳性率为86%(31/36)、75%(27/36)和69%(25/36),显著高于对照组的23%(3/13)、23%(3/13)和23%(3/13)(x2=4.5,P＜0.05).LRP在胆管癌年龄大于60岁组的表达阳性率93%(13/14)显著高于小于60岁组的64%(14/22)(X2=3.9,P＜0.05).上述指标与性别、年龄、病理分期、病理类型、分化程度和淋巴结转移均无明显相关(P>0.05);MRP,和GST-π在胆囊癌和胆管癌的表达具有相关性,Spearman系数=0.569(P＜0.05).结论 MRP.、LRP、GST-π在未经过化疗的胆囊癌和胆管癌组织中均有不同程度的高表达;胆囊癌和胆管癌的原发性多药耐药可能与MRP1、LRP、GST-π有关.

Expression of multidrug resistance-related proteins MRP1/LRP/GST-π in carcinoma of the gallbladder and cholangiocarcinoma

Objective To investigate the expression of muhidrug resistance-related protein 1 (MRP1),lung resistance-related protein(LfuP)and glutathione S-transferase-π(GST-π)in carcinoma of the gallbladder and cholangiocarcinoma. Methoils MRP1,LRP,GST-πwere measured in experimental group(18 cases of carcinoma of the gallbladder,36 CSSeS Of cholangiocarcinoma)and control group(13cases of cholecystitis and cholangeitis)by immunohistochemistry.Statistical analysis used chi-square test and spearman test. Results The positive rate of MRP1,LRP,GST-π in carcinoma of the gallbladder and eholangiocarcinoma were 72%(13/18),78%(14/18),61%(11/18)and 86%(31/36),75%(27/36),69%(25/36),respectively,significantly higher than those of 23%(3/13),23%(3/13),23%(3/13)(X2=4.5,P＜0.05)in control group.The expression of LRP93%(13/14)]in pafients＞60 years old was significantly higher than 64%(14/22)in patients younger than 60 yrs old(x2=3.9,P ＜0.05).In addition,their expression was not related to gender,age,staging,tumor differentiation and lymph node metastasis(P＞0.05).The expression of MRP1 was related with tllose Of GST-π,Spearman correlation coefficient=0.569(P＜0.05).Conclusions MRP1,LRP,GsT-π were over expressed in various degrees in carcinoma Of the gallbladder and cholangiocarcinoma witllout chemotherapy.and related to the primary muhidrug resistance Of cholangiocarcinoma and carcinoma of the gallbladder.